Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

INTRODUCTION: Migraine is a debilitating neurological condition, affecting up to 15% of Americans. Recent estimates from a long-term safety study of rimegepant showed evidence of decreased monthly migraine days (MMD) in people with episodic migraine treated with rimegepant 75 mg. The objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Karissa M., L’Italien, Gilbert, Popoff, Evan, Powell, Lauren, Croop, Robert, Thiry, Alexandra, Harris, Linda, Coric, Vladimir, Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478726/
https://www.ncbi.nlm.nih.gov/pubmed/34455556
http://dx.doi.org/10.1007/s12325-021-01897-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478726/
https://www.ncbi.nlm.nih.gov/pubmed/34455556
http://dx.doi.org/10.1007/s12325-021-01897-2

Ejemplares similares